DK2512474T3 - N-forbundne hydroxaminsyrederivativer, der kan anvendes som antibakterielle midler - Google Patents
N-forbundne hydroxaminsyrederivativer, der kan anvendes som antibakterielle midler Download PDFInfo
- Publication number
- DK2512474T3 DK2512474T3 DK10803646.8T DK10803646T DK2512474T3 DK 2512474 T3 DK2512474 T3 DK 2512474T3 DK 10803646 T DK10803646 T DK 10803646T DK 2512474 T3 DK2512474 T3 DK 2512474T3
- Authority
- DK
- Denmark
- Prior art keywords
- methyl
- butanamide
- methylsulfonyl
- hydroxy
- oxopyridin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Claims (16)
1. Forbindelse med formlen:
i eller et farmaceutisk acceptabelt salt deraf, hvor R1 står for CrC3 alkyl; R2 står for hydrogen eller C1-C3 alkyl; R3 står for hydrogen, halogen, CrC3alkyl, CrC3alkoxy, trifluoromethyl eller trifluoromethoxy; L er fraværende eller er repræsenteret ved en enhed, der er udvalgt fra gruppen bestående af CrC6 alkylen, som eventuelt kan være substitueret, hvor 6 hydrogenatomer erstattes med en substituent, der er udvalgt fra gruppen bestående af halogen, cyano, sulfonamid, imino, iminohydroxy, -0-Ra, -SRa og -NRaRb, hvor Ra og Rb hver især uafhængigt er repræsenteret ved hydrogen eller CrC6alkyl; C2-C6 alkenylen; C2-C6 alkynylen; -(CH2)p-0-(CH2)n, -(CH2)p-0-(CH2)z-0-(CH2)n-; n er repræsenteret ved et heltal, som ligger mellem 0 og 4; p er repræsenteret ved et heltal, som ligger mellem 0 og 4; q er repræsenteret ved et heltal, som ligger mellem 0 og 6; z er repræsenteret ved et heltal, som ligger mellem 1 og 4; D er repræsenteret ved en substituent, der er udvalgt fra gruppen bestående af: i) mættet eller delvis umættet (C3-Ci0)cycloalkyl, hvor cycloalkyl er et bicyklisk, forbundet bicyklisk eller tricyklisk alkylradikal, hvor hver cyklisk enhed har 3 til 10 carbonatomer, og hvor cycloalkylgruppen eventuelt kan være substitueret, hvor op til 4 hydrogenatomer er erstattet med en substituent eller substituenter, der er udvalgt fra gruppen bestående af halogen, cyano, nitro, hydroxy, (CrC6)alkyl, (CrC6)alkoxy, trifluoromethyl, trifluromethoxy, phosphate, oxo, - S02NR4R5, -(CH2)m-NR5-C(0)-R4, -(CH2)m-C(0)-N-R4R5, -C(0)-R4, -C(0)-0-R4,-SR4, -S02R4 og -NR4R5, hvor substituenterne kan være de samme eller forskellige; ii) (C6-Cio)aryl, eventuelt substituteret med op til 4 ikke-hydrogen substituen-ter, hvor hver substituent er uafhængigt udvalgt fra gruppen bestående af halogen, cyano, nitro, hydroxy, (CrC6)alkyl, (CrC6)alkoxy, trifluoromethyl, trifluromethoxy, phosphat, -S02NR4R5, -(CH2)m-NR5-C(0)-R4, -(CH2)m-C(0)-N-R4R5, -C(0)-R4, -C(0)-0-R4, -SR4, -S02R4 og -NR4R5, iii) heteroaryl, eventuelt substitueret, hvor op til 4 carbonatomer af heteroary-lenheden kan være substitueret med en substituent, hvor hver substituent er uafhængigt udvalgt fra gruppen bestående af halogen, cyano, nitro, hydroxy, (Ci-C6)alkyl, (CrC6)alkoxy, trifluoromethyl, trifluromethoxy, phosphat, S02NR4R5, -(CH2)m-N-C(0)-R4, -(CH2)m-C(0)-N-R4R5, -C(0)-R4, -C(0)-0-R4, -SR4, -S02R4 og -NR4R5, iv) heterocyklisk, eventuelt substitueret, hvor op til 4 carbonatomer af hetero-cyklusenhed kan være substitueret med en substituent, hvor hver substituent er uafhængigt udvalgt fra gruppen bestående af halogen, cyano, nitro, hydroxy, (CrCe)alkyl, (CrC6)alkoxy, trifluoromethyl, trifluromethoxy, phosphate, oxo, S02NR4R5, -(CH2)m-N-C(0)-R4, -(CH2)m-C(0)-N-R4R5, -C(0)-R4, -C(0)-0-R4, -SR4, -S02R4 og -NR4R5, T er fraværende eller er repræsenteret ved -S-(CH2)z-0-(CH2)n, -0-(CH2)z-S-(CH2)n, -(CH2)q-, -(CH2)n-C(0)-(CH2)p-, -(CH2)n-0-(CH2)p-, -(CH2)n-S-(CH2)p, S-C1-C6 alkylen, -O-C1-C6 alkylen, -0-(CH2)p-C(0)-(CH2)n-, -(CH2)p-C(0)-(CH2)q-0-(CH2)n-, -0-(CH2)z-0-(CH2)n-, -0-(CH2)z-0-(CH2)z-0-(CH2)n-, -S-(CH2)z-S-(CH2)n-, -(CH2)n-SH, eller -(CH2)n-OH, og; G er fraværende eller er repræsenteret ved en substituent, der er udvalgt fra gruppen bestående af: i) mættet eller delvis umættet (C3-Ci0)cycloalkyl, hvor cycloalkyl er et bicyklisk, forbundet bicyklisk eller tricyklisk alkylradikal, hvor hver cyklisk enhed har 3 til 10 carbonatomer, og hvor cycloalkylgruppen eventuelt kan være substitueret, hvor op til 4 hydrogenatomer er erstattet med en substituent eller substituenter, der er udvalgt fra gruppen bestående af halogen, cyano, nitro, hydroxy, (CrCeJalkyl, (CrC6)alkoxy, trifluoromethyl, trifluromethoxy, phosphate, oxo, - S02NR4R5, -(CH2)m-NR5-C(0)-R4, -(CH2)m-C(0)-N-R4R5, - C(0)-R4, -C(0)-0-R4,-SR4, -S02R4 og -NR4R5, hvor substituenterne kan være de samme eller forskellige; ii) (C6-Cio)aryl, eventuelt substitueret med op til 4 ikke-hydrogen substituen-ter, hvor hver substituent er uafhængigt udvalgt fra gruppen bestående af halogen, cyano, nitro, hydroxy, (CrC6)alkyl, (CrC6)alkoxy, trifluoromethyl, trifluromethoxy, phosphat, -S02NR4R5, -(CH2)m-NR5-C(0)-R4, -(CH2)m-C(0)-N-R4R5, -C(0)-R4, -C(0)-0-R4, -SR4, -S02R4 og -NR4R5; iii) heteroaryl, eventuelt substitueret, hvor op til 4 carbonatomer af heteroary-lenheden kan være substitueret med en substituent, hvor hver substituent er uafhængigt udvalgt fra gruppen bestående af halogen, cyano, nitro, hydroxy, (CrC6)alkyl, (CrC6)alkoxy, trifluoromethyl, trifluromethoxy, phosphat, S02NR4R5, -(CH2)m-N-C(0)-R4, -(CH2)m-C(0)-N-R4R5, -C(0)-R4, -C(0)-0-R4, - SR4, -S02R4 og -NR4R5, og; iv) heterocyklisk, eventuelt substitueret, hvor op til 4 carbonatomer af hetero-cyklusenheden kan være substitueret med en substituent, hvor hver substituent er uafhængigt udvalgt fra gruppen bestående af halogen, cyano, nitro, hydroxy, (CrC6)alkyl, (Ci-C6)alkoxy, trifluoromethyl, trifluromethoxy, phosphate, oxo, S02NR4R5, -(CH2)m-N-C(0)-R4, -(CH2)m-C(0)-N-R4R5, -C(0)-R4, -C(0)-0-R4, -SR4, -S02R4 og -NR4R5; R4 og R5 er hver især uafhængigt repræsenteret ved hydrogen eller CrC6 al kyl; og m er 0-4.
2. Forbindelse ifølge krav 1, hvor R1 og R2 hver især er methyl.
3. Forbindelse ifølge krav 1 eller 2, hvor R3 is hydrogen.
4. Forbindelse ifølge krav 2 eller 3, hvor forbindelsen er R-enantiomer.
5. Forbindelse ifølge et hvilket som helst af kravene 1,2, 3 eller 4, hvor L er fraværende.
6. Forbindelse ifølge et hvilket som helst af kravene 1,2, 3, 4 eller 5, hvor G og T er fraværende.
7. Forbindelse ifølge et hvilket som helst af kravene 1-6, hvor D er (C6-Cio)aryl eventuelt substitueret med op til 4 ikke-hydrogen substituenter, hvor hver substituent er uafhængigt udvalgt fra gruppen bestående af halogen, cyano, nitro, hydroxy, (Ci-C6)alkyl, (CrC6)alkoxy, trifluoromethyl, trifluro-methoxy, phosphat, -S02NR4R5, -(CH2)m-NR5-C(0)-R4, -(CH2)m-C(0)-N-R4R5, -C(0)-R4, -C(0)-0-R4, -SR4, -S02R4 og -NR4R5.
8. Forbindelse ifølge krav 6, hvor D er phenyl eventuelt substitueret med op til 4 ikke-hydrogensubstituenter, hvor hver substituent er uafhængigt udvalgt fra gruppen bestående af halogen, cyano, nitro, hydroxy, (CrC6)alkyl, (Cr C6)alkoxy, trifluoromethyl, trifluromethoxy, phosphat, -S02NR4R5, -(CH2)m-NR5-C(0)-R4, -(CH2)m-C(0)-N-R4R5, -C(0)-R4, -C(0)-0-R4, -SR4, -S02R4 og -NR4R5.
9. Forbindelse ifølge krav 1, der er udvalgt fra: (2R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-{2-oxo-4-[4-(1 H-pyrazol-1-yl)phenyl]pyridin-1 (2FI)-yl}butanamid; (2R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-{2-oxo-4-[(E)-2-phenylvinyl]pyridin-1 (2FI)-yl}butanamid; (2R)-2-methyl-2-(methylsulfonyl)-4-[2-oxo-4-(2-phenylethyl)pyridin-1 (2H)-yl]-N-(tetrahydro-2FI-pyran-2-yloxy)butanamid; (+/-)-4-[4-{4-[3-(4,4-Difluoropiperidin-1-yl)propoxy]phenyl}-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamid-hydrochlorid; (2R)-N-hydroxy-4-{4-[4-(cis-3-hydroxycyclobutyl)phenyl]-2-oxopyridin-1 (2H)-yl}-2-methyl-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-4-{4-[4-(trans-3-hydroxycyclobutyl)phenyl]-2-oxopyridin-1 (2H)-yl}-2-methyl-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-4-[4-{4-[(4-hydroxycyclohexyl)oxy]phenyl}-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-4-[4-{4-[(cis-4-hydroxycyclohexyl)methoxy]phenyl}-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-4-[4-{4-[(trans-4-hydroxycyclohexyl)methoxy]phenyl}-2-oxopyridin-1 (2FI)-yl]-2-methyl-2-(methylsulfonyl)butanamid; (2R)-4-[4-{2-Fluoro-4-[(trans-4-hydroxycyclohexyl)methoxy]phenyl}-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-4-[4-{4-[(4-hydroxy-4-methylcyclohexyl)oxy]phenyl}-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-4-[4-{4-[(3-hydroxy-3-methylcyclobutyl)methoxy]phenyl}-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)butanamid; (2R)-4-{4-[4-(3-cyanopropoxy)phenyl]-2-oxopyridin-1 (2H)-yl}-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-4-[4-(4-{[3-(hydroxymethyl)cyclobutyl]methoxy}phenyl)-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)butanamid; N-hydroxy-4-[4-{4-[(4-hydroxy-4-methylpentyl)oxy]phenyl}-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)butanamid; N-hydroxy-4-[4-(4-{[3-(hydroxymethyl)cyclobutyl]oxy}phenyl)-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-4-[4-{4-[(4-hydroxy-4-methylcyclohexyl)oxy]phenyl}-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-4-[4-(4-{[3-(1-hydroxy-1-methylethyl)cyclobutyl]oxy}phenyl)-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)butanamid; (2R)-4-[4-{3-fluoro-4-[(4-hydroxy-4-methylcyclohexyl)oxy]phenyl}-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamid; N-hydroxy-4-{4-[4-(2-hydroxy-2-methylpropoxy)phenyl]-2-oxopyridin-1 (2H)-yl}-2-methyl-2-(methylsulfonyl)butanamid; (2R)-4-[4-{4-[(3,4-dihydroxy-4-methylpentyl)oxy]phenyl}-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamid; (2R)-4-[4-{2-fluoro-4-[(cis-4-hydroxycyclohexyl)methoxy]phenyl}-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamid; (2R)-N-Hydroxy-2-methyl-2-(methylsulfonyl)-4-(2-oxo-4-phenylpyridin-1 (2H)-yl)butanamid; (2R)-4-[4-(2-fluoro-4-hydroxy-3-methylphenyl)-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamid; (2R)-4-[4-(2-fluoro-4-methylphenyl)-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamid; (2R)-4-[4-(2,3-difluorophenyl)-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamid; (2R)-4-[4-(4-chlorophenyl)-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-2-methyl-4-[4-(4-methylphenyl)-2-oxopyridin-1 (2H)-yl]-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-4-[4-(4-methoxyphenyl)-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)butanamid; (2R)-4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-2-methyl-4-[4-(2-methyl-1H-indol-5-yl)-2-oxopyridin-1 (2H)-yl]-2-(methylsulfonyl)butanamid; (2R)-4-[4-(4-chloro-2-fluorophenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2- methyl-2-(methylsulfonyl)butanamid; (2R)-4-[4-(2-fluoro-4-methoxyphenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2- methyl-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-[2-oxo-4-(2,3,6- trifluorophenyl)pyridin-1(2H)-yl]butanamid; (2R)-N-hydroxy-2-methyl-4-{4-[4-(2-methylpyrimidin-4-yl)phenyl]-2-oxopyridin-1 (2H)-yl}-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-2-methyl-4-{4-[4-(1-methyl-1 H-pyrazol-5-yl)phenyl]-2-oxopyridin-1 (2H)-yl}-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-2-methyl-4-{4-[4-(2-methyl-1,3-oxazol-4-yl)phenyl]-2-oxopyridin-1 (2H)-yl}-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-2-methyl-4-{4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2- oxopyridin-1 (2H)-yl}-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-2-methyl-4-{4-[4-(2-methylpyrimidin-5-yl)phenyl]-2- oxopyridin-1(2H)-yl}-2-(methylsulfonyl)butanamid; (2R)-4-{4-[4-(difluoromethoxy)-2-fluorophenyl]-2-oxopyridin-1(2H)-yl}-N- hydroxy-2-methyl-2-(methylsulfonyl)butanamid; N-Hydroxy-2-methyl-2-(methylsulfonyl)-4-{2-oxo-4-[4-(pyridin-2- yloxy)phenyl]pyridin-1(2H)-yl}butanamid; N-hydroxy-4-{4-[4-(3-hydroxypropoxy)phenyl]-2-oxopyridin-1(2H)-yl}-2- methyl-2-(methylsulfonyl)butanamid; N-Hydroxy-4-{4-[4-(3-hydroxypropyl)phenyl]-2-oxopyridin-1(2H)-yl}-2-methyl-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-4-[4-{4-[2-(3-hydroxycyclobutyl)ethoxy]phenyl}-2-oxopyridin- 1(2H)-yl]-2-methyl-2-(methylsulfonyl)butanamid; (+/-)-4-[4-(1-benzofuran-2-yl)-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamid; (+/-)-N-hydroxy-4-[4-(6-methoxy-2-naphthyl)-2-oxopyridin-1(2H)-yl]-2-methyl- 2-(methylsulfonyl)butanamid; N-Hydroxy-2-methyl-2-(methylsulfonyl)-4-[2-oxo-4-(4-pyridin-4-ylphenyl)pyridin-1 (2H)-yl]butanamid; N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(2-oxo-4-quinolin-7-ylpyridin-1(2H)- yl)butanamid; N-hydroxy-2-methyl-2-(methylsulfonyl)-4-{2-oxo-4-[4-(2-pyridin-4-ylethoxy)phenyl]pyridin-1 (2H)-yl}butanamid; (2R)-N-hydroxy-2-methyl-4-{4-[4-(5-methyl-1,3-oxazol-2-yl)phenyl]-2-oxopyridin-1(2H)-yl}-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-[2-oxo-4-(4-pyrimidin-2-ylphenyl)pyridin-1 (2H)-yl]butanamid; (2R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-{2-oxo-4-[4-(2H-1,2,3-triazol-2-yl)phenyl]pyridin-1 (2H)-yl}butanamid; 2R)-4-[4-(4-fluorophenyl)-2-oxopyridin-1(2H)-yl]-/\/-hydroxy-2-methyl-2- (methylsulfonyl)-butanamid; (2R)-4-[4-(3-fluorophenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-methyl-2- (methylsulfonyl)butanamid; (2R)-4-[4-(2-fluorophenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-methyl-2- (methylsulfonyl)butanamid; (2R)-4-[4-(2,3-difluoro-4-methoxyphenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2- methyl-2-(methylsulfonyl)butanamid; (2R)-4-[4-(3-chloro-2-fluorophenyl)-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamid; (2R)-4-[4-(2,3-dichlorophenyl)-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-{2-oxo-4-[4-(tetrahydro-2H-pyran-4-yl)phenyl]pyridin-1 (2H)-yl}butanamid; (2R)-N-hydroxy-4-[4-{4-[(2-methoxyethyl)thio]phenyl}-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)butanamid; (2R)-4-[4-(4-chloro-2,3-difluorophenyl)-2-oxopyNdin-1(2/-/)-yl]-N-hydroxy-2- methyl-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-[2-oxo-4-(2,3,4- trifluorophenyl)pyridin-1(2H)-yl]butanamid; 4-[4-(Benzyloxy)-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamid; N-Hydroxy-2-methyl-4-(3-methyl-2-oxo-4-phenylpyridin-1 (2H)-yl)-2-(methylsulfonyl)butanamid; 4-((4-Cyclohexyl-2-oxopyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamid;
2-Ethyl-N-hydroxy-2-(methylsulfonyl)-4-(2-oxo-4-phenylpyridin-1 (2H)-yl)butanamid; (2R)-4-(3-fluoro-2-oxo-4-phenylpyridin-1 (2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamid; (2R)-4-(5-fluoro-2-oxo-4-phenylpyridin-1 (2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamid; 2-(ethylsulfonyl)-N-hydroxy-2-methyl-4-(2-oxo-4-phenylpyridin-1 (2H)-yl)butanamid; (2R)-N-hydroxy-4-{4-[4-(4-methoxy-2H-1,2,3-triazol-2-yl)phenyl]-2-oxopyridin-1(2H)-yl}-2-methyl-2-(methylsulfonyl)butanamid; (2R)-4-[4-{4-[(6-methoxypyridin-3-yl)methoxy]phenyl}-2-oxopyridin-1 (2H)-yl]- 2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamid; (2R)-4-[4-{4-[difluoro(trans-4-hydroxycyclohexyl)methoxy]phenyl}-2- oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-4-[4-{4-[4-(hydroxymethyl)piperidin-1-yl]phenyl}-2-oxopyridin- 1(2H)-yl]-2-methyl-2-(methylsulfonyl)butanamid; N-hydroxy-4-[4-{4-[(1 E)-N-methoxyethanimidoyl]phenyl}-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)butanamid; N-Hydroxy-4-[4-{4-[3-(hydroxymethyl)isoxazol-5-yl]-3-methylphenyl}-2-oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)butanamid; (2R)-N-Hydroxy-2-methyl-2-(methylsulfonyl)-4-[2-oxo-4-(3-phenylazetidin-1-yl)pyridin-1 (2H)-yl]butanamid; (2R)-N-Hydroxy-2-methyl-2-(methylsulfonyl)-4-[2-oxo-4-(phenylethynyl)pyridin-l (2H)-yl]butanamid; 4-[4-(3-Cyclohexylpropoxy)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-methyl-2- (methylsulfonyl)butanamid; (2R)-N-Hydroxy-2-methyl-2-(methylsulfonyl)-4-(2-oxo-1'-pyrimidin-2-yl-1 ',2',3',6'-tetrahydro-4,4'-bipyridin-1 (2H)-yl)butanamid; (2R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-[4-(2-naphthyl)-2-oxopyridin-1(2H)-yl]butanamid; (2R)-4-[4-(4-chloro-3-fluorophenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2- methyl-2-(methylsulfonyl)butanamid; (2R)-4-[4-(3,4-dichlorophenyl)-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl) butanamid; (2R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-{2-oxo-4-[4-(1,3-thiazol-2- yl)phenyl]pyridin-1(2H)-yl}butanamid; (2R)-4-[4-(2-chloro-3-methylphenyl)-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl) butanamid; (2R)-N-hydroxy-4-[4-(4-isoxazol-3-ylphenyl)-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl) butanamid; (2R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-[2-oxo-4-(4- propionylphenyl)pyridin-1(2H)-yl]butanamid; (2R)-N-hydroxy-4-{4-[4-(cis-3-hydroxy-3-methylcyclobutyl)phenyl]-2-oxopyridin-1(2H)-yl}-2-methyl-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-{2-oxo-4-[4-(trifluoromethyl)phenyl]pyridin-1 (2H)-yl}butanamid; (2R)-N-hydroxy-2-methyl-4-{3-methyl-2-oxo-4-[4-(2H-1,2,3-triazol-2-yl)phenyl]pyridin-1 (2H)-yl}-2-(methylsulfonyl)butanamid; (2R)-4-(4-cyclohex-1 -en-1 -yl-2-oxopyridin-1 (2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamid; (2R)-4-(4-cyclohept-1 -en-1 -yl-2-oxopyridin-1 (2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-4-[4-{4-[(3-hydroxycyclobutyl)methyl]phenyl}-2-oxopyridin- 1(2H)-yl]-2-methyl-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-4-[4-{6-[(1 S)-1 -hydroxyethyl]-2-naphthyl}-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)butanamid; N-hydroxy-4-[4-(6-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-2-oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)butanamid; (2R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-[2-oxo-4-(5-phenyl-2-thienyl)pyridin-1 (2H)-yl]butanamid; N-hydroxy-4-{4-[4-(1-hydroxyethyl)phenyl]-2-oxopyridin-1(2H)-yl}-2-methyl-2- (methylsulfonyl)butanamid; N-hydroxy-2-methyl-4-[4-(1 -methyl-1 H-indol-2-yl)-2-oxopyridin-1 (2H)-yl]-2-(methylsulfonyl)butanamid; 4-[4-(2-cyclopentylethoxy)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-methyl-2- (methylsulfonyl)butanamid; N-hydroxy-2-methyl-2-(methylsulfonyl)-4-[2-oxo-4-(2-phenylethoxy)pyridin-1 (2H)-yl]butanamid; og 4-[4-(4-acetylphenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-methyl-2- (methylsulfonyl)butanamid; eller et farmaceutisk acceptabelt salt deraf.
10. Forbindelse ifølge krav 1, som er (2R)-N-hydroxy-2-methyl-2- (methylsulfonyl)-4-{2-oxo-4-[4-(2H-1,2,3-triazol-2-yl)phenyl]pyridin-1 (2H)-yl}butanamid; eller et farmaceutisk acceptabelt salt deraf.
11. Forbindelse ifølge krav 1, som er (2R)-4-[4-(2,3-difluoro-4- methoxyphenyl)-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2- (methylsulfonyl)butanamid; eller et farmaceutisk acceptabelt salt deraf.
12. Forbindelse ifølge krav 1, som er (2R)-N-hydroxy-4-{4-[4-(4-methoxy-2FI- 1,2,3-triazol-2-yl)phenyl]-2-oxopyridin-1 (2FI)-yl}-2-methyl-2-(methylsulfonyl)butanamid; eller et farmaceutisk acceptabelt salt deraf.
13. Forbindelse ifølge krav 1, som er (2R)-N-hydroxy-2-methyl-2- (methylsulfonyl)-4-{2-oxo-4-[4-(1,3-thiazol-2-yl)phenyl]pyridin-1 (2H)-yl}butanamid; eller et farmaceutisk acceptabelt salt deraf.
14. Forbindelse ifølge et hvilket som helst af kravene 1 til 13, i kombination med et eller flere yderligere antibakterielle midler.
15. Farmaceutisk sammensætning omfattende en forbindelse ifølge et af kravene 1-13 i blanding med mindst ét farmaceutisk acceptabelt hjælpestof.
16. Forbindelse ifølge et hvilket som helst af kravene 1-13 til anvendelse i behandling af bakterieinfektioner
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28703509P | 2009-12-16 | 2009-12-16 | |
PCT/IB2010/055596 WO2011073845A1 (en) | 2009-12-16 | 2010-12-06 | N-linked hydroxamic acid derivatives useful as antibacterial agents |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2512474T3 true DK2512474T3 (da) | 2014-12-01 |
Family
ID=43571291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10803646.8T DK2512474T3 (da) | 2009-12-16 | 2010-12-06 | N-forbundne hydroxaminsyrederivativer, der kan anvendes som antibakterielle midler |
Country Status (10)
Country | Link |
---|---|
US (4) | US8664401B2 (da) |
EP (1) | EP2512474B1 (da) |
JP (2) | JP5793766B2 (da) |
CA (2) | CA2899583A1 (da) |
DK (1) | DK2512474T3 (da) |
ES (1) | ES2525820T3 (da) |
PL (1) | PL2512474T3 (da) |
PT (1) | PT2512474E (da) |
SI (1) | SI2512474T1 (da) |
WO (1) | WO2011073845A1 (da) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201716375A (zh) | 2007-06-12 | 2017-05-16 | Achaogen Inc | 抗菌劑 |
WO2010032147A2 (en) | 2008-09-19 | 2010-03-25 | Pfizer Inc. | Hydroxamic acid derivatives useful as antibacterial agents |
JP5793766B2 (ja) | 2009-12-16 | 2015-10-14 | ファイザー・インク | 抗菌剤として有用なn−結合型ヒドロキサム酸誘導体 |
WO2012031298A2 (en) | 2010-09-03 | 2012-03-08 | Duke University | Ethynylbenzene derivatives |
GEP20156370B (en) * | 2011-03-07 | 2015-09-25 | Pfizer | Fluoro-pyridinone derivatives useful as antibacterial agents |
AU2012238379C1 (en) | 2011-04-08 | 2015-08-06 | Pfizer Inc. | Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents |
CA2830920C (en) | 2011-04-08 | 2015-07-14 | Pfizer Inc. | Isoxazole derivatives useful as antibacterial agents |
WO2013170165A1 (en) * | 2012-05-10 | 2013-11-14 | Achaogen, Inc. | Antibacterial agents |
RU2617842C2 (ru) * | 2012-11-08 | 2017-04-28 | Пфайзер Инк. | Гетероароматические соединения и их применение в качестве допаминовых D1 лигандов |
WO2014165075A1 (en) | 2013-03-12 | 2014-10-09 | Achaogen, Inc. | Antibacterial agents |
US10647664B2 (en) | 2013-08-16 | 2020-05-12 | Duke University | Substituted hydroxamic acid compounds |
WO2015024016A2 (en) | 2013-08-16 | 2015-02-19 | Duke University | 2-piperidinyl substituted n,3-dihydroxybutanamides |
WO2015024011A2 (en) | 2013-08-16 | 2015-02-19 | Duke University | Antibacterial compounds |
US10112960B2 (en) | 2013-09-05 | 2018-10-30 | Dow Agrosciences Llc | Methods for producing borylated arenes |
AR097617A1 (es) | 2013-09-13 | 2016-04-06 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos del 2h-indazol |
EP2860177A3 (en) * | 2013-09-20 | 2015-06-10 | Bayer Intellectual Property GmbH | Synthesis of functionalized arenes |
PL3083567T3 (pl) | 2013-12-19 | 2018-08-31 | Idorsia Pharmaceuticals Ltd | Przeciwbakteryjne pochodne 1h-indazolu i 1h-indolu |
AR099612A1 (es) | 2014-03-04 | 2016-08-03 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona |
WO2015164458A1 (en) | 2014-04-22 | 2015-10-29 | Novartis Ag | Isoxazoline hydroxamic acid derivatives as lpxc inhibitors |
WO2015162518A1 (en) * | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
JP6564394B2 (ja) | 2014-04-28 | 2019-08-21 | ファイザー・インク | 複素環式化合物およびそのドーパミンd1リガンドとしての使用 |
EP3143007B1 (en) * | 2014-05-16 | 2018-07-11 | Idorsia Pharmaceuticals Ltd | Antibacterial quinazoline-4(3h)-one derivatives |
TW201625354A (zh) | 2014-06-16 | 2016-07-16 | 陶氏農業科學公司 | 用於製備氧硼基化芳烴之方法 |
CA2963875A1 (en) | 2014-11-19 | 2016-05-26 | Actelion Pharmaceuticals Ltd | Antibacterial benzothiazole derivatives |
CR20170260A (es) | 2014-12-16 | 2017-08-21 | Novartis Ag | COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC |
AR105646A1 (es) | 2015-08-11 | 2017-10-25 | Actelion Pharmaceuticals Ltd | Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida |
AR105889A1 (es) * | 2015-09-03 | 2017-11-22 | Actelion Pharmaceuticals Ltd | Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos |
JP2019501896A (ja) * | 2015-12-08 | 2019-01-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 抗菌化合物としての置換ベンザジノン |
EP3458453A1 (en) * | 2016-05-17 | 2019-03-27 | Idorsia Pharmaceuticals Ltd | 6-(buta-1,3-diyn-1-yl)benzo[d]thiazole derivatives |
WO2017216705A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent |
WO2017223349A1 (en) | 2016-06-23 | 2017-12-28 | Achaogen, Inc. | Antibacterial agents |
MA48994A (fr) | 2017-03-30 | 2020-02-05 | Hoffmann La Roche | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 |
KR20200120924A (ko) * | 2018-02-10 | 2020-10-22 | 케이비피 바이오사이언시즈 씨오., 엘티디. | 항생제로서 작용하는 화합물 |
EP3765027A1 (en) * | 2018-03-15 | 2021-01-20 | Pfizer Inc | Pyridinone and pyrimidinone phosphates and boronates useful as antibacterial agents |
US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
WO2023015236A2 (en) * | 2021-08-04 | 2023-02-09 | The Research Foundation For The State University Of New York | Composition and method for treatment of gram negative bacterial infection |
WO2023192356A1 (en) | 2022-03-30 | 2023-10-05 | Zoetis Services Llc | Intermediates useful for the preparation of an lpxc analog, and processes for their preparation |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3995042A (en) * | 1973-09-07 | 1976-11-30 | E. R. Squibb & Sons, Inc. | Pyridine containing compounds |
US4769461A (en) | 1986-09-16 | 1988-09-06 | American Home Products Corporation | Quinolinyl benzene hydroxamic acids as anti-inflammatory/antiallergic agents |
US5110831A (en) | 1990-11-30 | 1992-05-05 | Du Pont Merck Pharmaceutical Company | Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors |
DE69917221T2 (de) | 1998-02-07 | 2005-05-04 | Vernalis (Oxford) Ltd., Abington | Antibakterielle mittel |
GB9925470D0 (en) | 1999-10-27 | 1999-12-29 | Smithkline Beecham Plc | Novel compounds |
US6852752B2 (en) | 1999-12-17 | 2005-02-08 | Vicuron Pharmaceuticals Inc. | Urea compounds, compositions and methods of use and preparation |
JPWO2002074298A1 (ja) | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Il−6産生阻害剤 |
ES2180456B1 (es) | 2001-07-20 | 2004-05-01 | Laboratorios S.A.L.V.A.T., S.A. | Isoxazoles sustituidos y su utilizacion como antibioticos. |
CN102267924A (zh) * | 2003-01-08 | 2011-12-07 | 诺华疫苗和诊断公司 | 抗菌剂 |
GB0302431D0 (en) | 2003-01-30 | 2003-03-05 | Glaxo Group Ltd | Novel compounds |
US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
AU2005313912A1 (en) | 2004-12-10 | 2006-06-15 | Emory University | 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation |
WO2006118155A1 (ja) | 2005-04-27 | 2006-11-09 | Ishihara Sangyo Kaisha, Ltd. | ビフェニル誘導体又はその塩、並びにそれらを有効成分として含有する農園芸用殺菌剤 |
WO2006124897A2 (en) | 2005-05-13 | 2006-11-23 | Lexicon Genetics Incorporated | Methods and compositions for improving cognition |
US8088804B2 (en) * | 2005-12-15 | 2012-01-03 | Pfizer Inc. | N-hydroxyamide derivatives possessing antibacterial activity |
US20090318431A1 (en) | 2006-02-14 | 2009-12-24 | Pfizer Inc. | Benzoxazinone and benzoxazepinone oxazolidinones as antibacterial agents |
US20080085893A1 (en) | 2006-10-06 | 2008-04-10 | Shyh-Ming Yang | Matrix metalloprotease inhibitors |
CN101016270B (zh) | 2006-12-30 | 2012-05-09 | 天津药物研究院 | 取代的哌嗪基苯基异噁唑啉衍生物及其用途 |
US7879911B2 (en) * | 2007-02-01 | 2011-02-01 | Johnson Alan T | Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning |
WO2008105515A1 (ja) | 2007-02-28 | 2008-09-04 | Taisho Pharmaceutical Co., Ltd. | 新規なヒドロキサム酸誘導体 |
US20080234297A1 (en) | 2007-03-20 | 2008-09-25 | Changgeng Qian | HSP90 Inhibitors Containing a Zinc Binding Moiety |
US20110212080A1 (en) | 2008-08-04 | 2011-09-01 | Umar Faruk Mansoor | Urea derivatives as antibacterial agents |
JP5455913B2 (ja) | 2008-08-27 | 2014-03-26 | 大正製薬株式会社 | ナフチリジン−n−オキシドを有する新規ヒドロキサム酸誘導体 |
US8372885B2 (en) | 2008-09-17 | 2013-02-12 | Novartis Ag | Organic compounds and their uses |
WO2010032147A2 (en) | 2008-09-19 | 2010-03-25 | Pfizer Inc. | Hydroxamic acid derivatives useful as antibacterial agents |
WO2010100475A1 (en) | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
CA2774250C (en) * | 2009-10-13 | 2013-12-17 | Pfizer Inc. | C-linked hydroxamic acid derivatives useful as antibacterial agents |
JP5793766B2 (ja) | 2009-12-16 | 2015-10-14 | ファイザー・インク | 抗菌剤として有用なn−結合型ヒドロキサム酸誘導体 |
GEP20156370B (en) | 2011-03-07 | 2015-09-25 | Pfizer | Fluoro-pyridinone derivatives useful as antibacterial agents |
AU2012238379C1 (en) | 2011-04-08 | 2015-08-06 | Pfizer Inc. | Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents |
CA2830920C (en) | 2011-04-08 | 2015-07-14 | Pfizer Inc. | Isoxazole derivatives useful as antibacterial agents |
-
2010
- 2010-12-06 JP JP2012543942A patent/JP5793766B2/ja active Active
- 2010-12-06 CA CA2899583A patent/CA2899583A1/en not_active Abandoned
- 2010-12-06 US US13/515,607 patent/US8664401B2/en active Active
- 2010-12-06 WO PCT/IB2010/055596 patent/WO2011073845A1/en active Application Filing
- 2010-12-06 PT PT108036468T patent/PT2512474E/pt unknown
- 2010-12-06 CA CA2782453A patent/CA2782453C/en active Active
- 2010-12-06 PL PL10803646T patent/PL2512474T3/pl unknown
- 2010-12-06 SI SI201030802T patent/SI2512474T1/sl unknown
- 2010-12-06 DK DK10803646.8T patent/DK2512474T3/da active
- 2010-12-06 EP EP10803646.8A patent/EP2512474B1/en active Active
- 2010-12-06 ES ES10803646.8T patent/ES2525820T3/es active Active
-
2014
- 2014-01-14 US US14/154,239 patent/US8846933B2/en active Active
- 2014-07-31 US US14/447,788 patent/US9018384B2/en active Active
-
2015
- 2015-03-12 US US14/656,123 patent/US9180123B2/en active Active
- 2015-07-16 JP JP2015142292A patent/JP2016006064A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2512474B1 (en) | 2014-11-05 |
JP2013514345A (ja) | 2013-04-25 |
JP5793766B2 (ja) | 2015-10-14 |
PT2512474E (pt) | 2014-12-23 |
US9018384B2 (en) | 2015-04-28 |
EP2512474A1 (en) | 2012-10-24 |
ES2525820T3 (es) | 2014-12-30 |
US8664401B2 (en) | 2014-03-04 |
CA2782453A1 (en) | 2011-06-23 |
SI2512474T1 (sl) | 2014-12-31 |
WO2011073845A1 (en) | 2011-06-23 |
US20140343031A1 (en) | 2014-11-20 |
US20150182513A1 (en) | 2015-07-02 |
CA2782453C (en) | 2015-11-24 |
US20120258948A1 (en) | 2012-10-11 |
CA2899583A1 (en) | 2011-06-23 |
US9180123B2 (en) | 2015-11-10 |
US20140128363A1 (en) | 2014-05-08 |
PL2512474T3 (pl) | 2015-03-31 |
US8846933B2 (en) | 2014-09-30 |
JP2016006064A (ja) | 2016-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2512474T3 (da) | N-forbundne hydroxaminsyrederivativer, der kan anvendes som antibakterielle midler | |
AU2012226473B8 (en) | Fluoro-pyridinone derivatives useful as antibacterial agents | |
US8853258B2 (en) | C-linked hydroxamic acid derivatives useful as antibacterial agents | |
EP0605031B1 (en) | Phenoxy- and phenoxyalkyl-piperidines as antiviral agents | |
CN111867600A (zh) | 用作抗菌剂的吡啶酮和嘧啶酮磷酸盐和硼酸盐 | |
AU2015215883A1 (en) | Fluoro-pyridinone derivatives useful as antibacterial agents | |
OA16551A (en) | Fluoro-pyridinone derivatives useful as antibacterial agents. | |
NZ614205B2 (en) | Fluoro-pyridinone derivatives useful as antibacterial agents |